LOXO-292
E561037
LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
All labels observed (1)
| Label | Occurrences |
|---|---|
| LOXO-292 canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T6003723 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: LOXO-292 Context triple: [Loxo Oncology, developedDrug, LOXO-292]
-
A.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
B.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
C.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
D.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
E.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: LOXO-292 Target entity description: LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
-
A.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
B.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
C.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
D.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
E.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
small molecule drug
ⓘ
targeted cancer therapy ⓘ tyrosine kinase inhibitor ⓘ |
| belongsToDrugClass |
antineoplastic and immunomodulating agents
ⓘ
protein kinase inhibitors ⓘ |
| designedFor | RET-altered cancers ⓘ |
| hasATCCode | L01EX19 ⓘ |
| hasBlackBoxWarning |
QT interval prolongation
ⓘ
hemorrhagic events ⓘ hepatotoxicity ⓘ hypersensitivity reactions ⓘ hypertension ⓘ |
| hasBrandName | Retevmo ⓘ |
| hasClinicalTrialIdentifier |
LIBRETTO-001
ⓘ
LIBRETTO-121 ⓘ LIBRETTO-321 ⓘ
linked to:
LIBRETTO-121
|
| hasDeveloper |
Eli Lilly and Company
ⓘ
Loxo Oncology ⓘ
linked to:
Loxo Oncology (acquired)
|
| hasEffect |
inhibition of RET-mediated signaling pathways
ⓘ
reduction of tumor growth in RET-altered cancers ⓘ |
| hasInternationalNonproprietaryName | selpercatinib ⓘ |
| hasMolecularTarget |
RET
ⓘ
RET activating mutations ⓘ RET fusions ⓘ |
| hasRegulatoryAgency |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| hasSynonym |
Retevmo
ⓘ
selpercatinib ⓘ |
| hasUSFDADesignation |
breakthrough therapy
ⓘ
orphan drug ⓘ priority review ⓘ |
| indication |
RET fusion-positive non-small cell lung cancer
ⓘ
RET fusion-positive thyroid cancer ⓘ RET-mutant medullary thyroid carcinoma ⓘ advanced or metastatic RET-altered solid tumors ⓘ |
| isAdministeredAs | oral capsules ⓘ |
| isIndicatedFor |
adult and pediatric patients 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer
ⓘ
adult and pediatric patients 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer ⓘ adult patients with RET fusion-positive non-small cell lung cancer ⓘ |
| isMetabolizedBy | CYP3A4 ⓘ |
| isSelectiveFor | RET over other kinases ⓘ |
| mechanismOfAction | selective RET receptor tyrosine kinase inhibition ⓘ |
| receivedUSFDAApprovalFor |
advanced or metastatic RET fusion-positive thyroid cancer
ⓘ
advanced or metastatic RET-mutant medullary thyroid cancer ⓘ metastatic RET fusion-positive non-small cell lung cancer ⓘ |
| routeOfAdministration | oral ⓘ |
| targets | RET kinase ⓘ |
| usedInCombinationWith | other anticancer therapies in some treatment regimens ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: LOXO-292 Description of subject: LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject linked to:
Loxo Oncology (acquired)
subject linked to:
Loxo Oncology (acquired)